Numerous MNK inhibitors (e.g., BAY1143269, Tomivosertib, CGP 57380, and ETC-206) have been tested in various clinical trials as a potential therapeutic strategy for cancer treatment [60]. This evidence concerns the gene ATP7A and cancer.